Arginase Gold™ Assays

Arginase gold icoon_scThe Arginase Gold™ assay technology is based on the detection of Arginase-1 activity with the proprietary probe Arginase Gold™. The probe gives a fluorescent signal in the presence of arginine and is quenched in the presence of ornithine (Figure 1). Arginase Gold™ is a homogenous mix-and-measure (‘addition only’) assay. Arginine is detected by a single incubation step at room temperature. The assay makes use of a fluorescence readout and is robust (Z’-factor > 0.6). Progression of the assay can be followed in real time, allowing for kinetic experiments. Arginase Gold™ was especially developed for use in multi-well plates and for high-throughput screening.

Figure 1. Schematic representation of Arginase Goldassay. Enzymatic conversion of L-arginine to L-ornithine is allowed to proceed for 60 minutes, after which the progress of the reaction can be measured immediately with fluorescence detection at 510 nm.


Arginase-1 is an enzyme that converts L-arginine into L-ornithine. Arginase-1 is an important drug target for cancer immunotherapy. Full-length Arginase-1 was recombinantly expressed and purified from E. coli. Purified Arginase-1 catalytically converts L-arginine into L-ornithine.

• The signal of Arginase Gold™ is linearly proportional to the L-arginine and L-ornithine ratio at a concentration range up to 2.5 mM (Figure 2).
• Arginase Gold™ is ideally suited for high-throughput screening of compound libraries.

Figure 2. Arginase Gold™ calibration curve with concentrations of L-arginine and L-ornithine in the assay. B. Dose response curve of the Arginase-1 reference inhibitor ABH generated with the assay.


• Enzymatic activity is measured in a homogenous assay format. Only two addition steps are required before readout.
• Short incubation times at room temperature and mild reaction conditions allow operation on high-throughput robotic systems in 384-wells plates.
• Robust assay suitable for high-throughput screening.
• Inhibition of Arginase-1 results in gain of signal.
• Kinetic experiments and end-point measurements can be performed with the same kit.
• Fluorescent read-out is less prone to interference, in contrast to the standard colorimetric urea assay.
• The assay can be performed in a short time, it only takes 1.5 hours from the start of the reaction to fluorescence detection.

The Arginase Gold™ kit can be ordered directly from NTRC as a 1,000 data points ready to use kit. The product number is NTRC-hARG-1K. The kit includes Arginase-1 enzyme, substrate, detection reagent and reference inhibitor. Please contact us for custom-based large quantities or to order components separately.

For more information and request for a quotation, please send an e-mail to

Arginase Gold™ Products

Catalog No. Product Name Product Size
hARG assay kit 1,000 datapoints

  • Jun 15 2020   NTRC, Pelago Bioscience and Pangaea Oncology to collaborate in Eurostars project to develop a novel biomarker platform for immuno-oncology
  • May 18 2020   Novel screening assay for Arginase-1 inhibitors published in SLAS Discovery
  • Nov 29 2019   New structural insights into Arginase-1, a target for cancer immunotherapy
  • Nov 5 2019   Approach for Predictive Precision Medicine at ELRIG 2019 Drug Discovery Conference
  • Oct 21 2019   Predictive Precision Medicine Approaches at Molecular Targets and Cancer Therapeutics Conference
  • Mar 27 2019   NTRC and Radboud explore new methods to predict chemotherapy response in ovarian cancer
  • Mar 20 2019   Effective discovery of synergistic combinations by in silico prioritization
  • Feb 12 2019   Tissue-type analysis included in Oncolines™ cancer cell line profiling
  • Nov 21 2018   NTRC expands ResidenceTimer™ kinase panel with CDKs, MERTK, TYRO3 and GSKβ
  • Nov 12 2018   NTRC launches the first High-throughput Screening Assay for Arginase-1 inhibitors at ENA2018
  • Nov 1 2018   New predictive drug response biomarkers for approved kinase inhibitors
  • Oct 28 2018   NTRC presents at Rare Diseases and Orphan Drugs conference
  • Sep 26 2018   Oncolines™ at Discovery on Target conference in Boston
  • Jun 29 2018   NTRC presents at European Association of Cancer Research conference in Amsterdam
  • Jun 10 2018   NTRC expands OncolinesProfiler™ reference compound database to 162 anti-cancer agents
  • Apr 11 2018   NTRC presents novel high-throughput screening assay for Arginase I inhibitors for cancer immunotherapy at AACR Annual Meeting in Chicago
  • Apr 5 2018   NTRC expands ResidenceTimer™ platform with BTK resistance mutants
  • Mar 25 2018   NTRC expands SynergyFinder™ platform with triple combination testing
  • Feb 22 2018   NTRC includes Growth Rate metric evaluation in Oncolines™ profiling
  • Nov 15 2017   NTRC at Pivot Oncology conference Breakthroughs in Precision Cancer Treatment
  • Nov 10 2017   Target residence time-guided lead optimization at the European Pharma Summit in Berlin
  • Oct 16 2017   Pharmacogenomic analysis at Molecular Targets and Cancer Therapeutics conference
  • Oct 11 2017   Novel synergistic combinations identified by unbiased high-throughput screening
  • Sep 25 2017   NTRC’s key TTK kinase inhibitor patent granted in US
  • Sep 19 2017   Meet NTRC at Discovery on Target conference in Boston 25 – 29 September, 2017
  • Jul 28 2017   NTRC publishes an association of CTNNB1 mutant status and increased cancer cell line sensitivity to TTK inhibitors
  • Jun 23 2017   NTRC expands Oncolines™ cell line panel to 102 cell lines
  • May 22 2017   NTRC publishes target residence time-guided optimization of TTK inhibitors
  • Mar 30 2017   NTRC launches GeneNominator™ tool for drug sensitivity and gene expression analysis
  • Mar 27 2017   Meet NTRC at booth #3050 AACR 2017 in Washington D.C.
  • Mar 16 2017   New study in Oncotarget shows that stable aneuploid cells are more sensitive to TTK inhibition than chromosomally unstable cell lines
  • Jan 2 2017   Kinetic parameters of 80 kinase inhibitors available online through the Journal of Molecular Biology
  • Dec 23 2016   Structural insight into the function of TDO in healthy aging
  • Dec 23 2016   New drug combinations addressing treatment resistance in childhood leukemia proposed based on SynergyFinder™
  • Dec 5 2016   NTRC’s Oncolines™ profiling is cover story in December issue of Molecular Cancer Therapeutics
  • Nov 10 2016   NTRC presents on ResidenceTimer™ and OncolinesProfiler™ at 28th EORTC-NCI-AACR symposium in Munich
  • Sep 18 2016   NTRC to join EU mission to Japan and to present at BIO Japan
  • Sep 2 2016   Comparative Oncolines™ profiling of 122 anti-cancer agents published in Molecular Cancer Therapeutics
  • Aug 25 2016   NTRC presents on ResidenceTimer™ at Discovery on Target conference in Boston
  • Jul 6 2016   NTRC presents OncolinesProfiler™ and TTK program at EACR in Manchester
  • Apr 28 2016   Novel synergistic drug combinations proposed for pediatric T-cell leukemia
  • Apr 8 2016   NTRC expands number of cancer genes analyzed in Oncolines™ cell line panel
  • Apr 8 2016   NTRC presents on TTK kinase program at AACR conference
  • Jan 15 2016   NTRC team of cyclists will conquer the Alpe d’Huez to raise funds for cancer research
  • Dec 9 2015   NTRC has identified IDO1 inhibitors with best-in-class properties by screening at the European Lead Factory
  • Dec 4 2015   NTRC and Vipergen receive Eurostars support for cancer immunotherapy research
  • Sep 14 2015   NTRC launches comparative cancer cell line profiling
  • Aug 31 2015   NTRC presents at Discovery on Target conference in Boston
  • Jul 10 2015   Novel therapeutic target proposed to increase the efficacy of taxane chemotherapy
  • Jul 8 2015   Whole genome doubling causes multidrug resistance
  • Jun 14 2015   NFK GreenScreen™ and TTK program presented at EACR-AACR conference in Florence
  • May 27 2015   Selective targeting of cancer driver genes by combinations of existing drugs published in PLOS ONE
  • Apr 28 2015   TTK drug discovery program presented at Protein Kinases conference in Berlin
  • Apr 7 2015   SynergyFinder™ presented at AACR 2015 in Philadelphia
  • Apr 7 2015   ResidenceTimer™ and TTK drug discovery program presented at Drug Discovery Chemistry meeting in San Diego
  • Apr 3 2015   NTRC receives Michael J. Fox Foundation support for TDO program for Parkinson’s disease
  • Feb 22 2015   TTK program and SynergyFinder™ presented at TAT 2015 conference in Paris
  • Feb 18 2015   NTRC receives qualified hit series for TDO from the European Lead Factory
  • Jan 15 2015   NTRC launches assay for mouse IDO1 and mouse TDO activity
  • Jan 7 2015   NTRC and Utrecht University start collaborative research project on Parkinson’s disease
  • Nov 12 2014   SynergyFinder™ and NFK GreenScreen™ presented at EORTC-NCI-AACR conference in Barcelona
  • Nov 12 2014   NFK GreenScreen™ presented at CHAINS conference in Veldhoven
  • Oct 1 2014   NTRC launches Oncolines™ 66 cell line panel
  • Sep 5 2014   ResidenceTimer™ will be presented at the EFMC-ISMC symposium 2014
  • Aug 25 2014   Reverse Phase Protein Array workshop in Paris sponsored by NTRC
  • Aug 25 2014   NTRC will present at 8th International Protein Kinase Inhibitors conference in Warsaw
  • Jun 27 2014   Oncolines™ and SynergyFinder™ presented at EACR 2014 in Munich
  • Jun 2 2014   NTRC publishes high-throughput screening assay for IDO1 and TDO in Journal of Biomolecular Screening
  • May 14 2014   NTRC will present at Discovery Partnerships Conference in Berlin
  • May 5 2014   NTRC will attend BIO 2014 in San Diego
  • May 5 2014   NTRC will present at Protein Kinases in Drug Discovery Conference in Berlin
  • Apr 13 2014   NTRC launches new service ResidenceTimer™ at Drug Discovery Chemistry conference in San Diego
  • Mar 27 2014   Oncolines™ and kinome profiling presented at AACR 2014 in San Diego
  • Mar 21 2014   NTRC publishes Oncolines™ profiles of all marketed small molecule kinase inhibitor drugs in PLOS ONE
  • Mar 7 2014   NTRC will present at Drug Discovery Innovations Conference 2014
  • Feb 15 2014   NTRC will present at Frontiers in Medicinal Chemistry 2014 in Tübingen.
  • Feb 6 2014   NTRC will present at BioEurope Spring 2014
  • Feb 6 2014   NTRC reaches new milestones in their drug discovery programs and expands business development activities
  • Dec 10 2013   NTRC extends the roll-out of its services Oncolines™ and SynergyFinder™ and the kinase profiling services of Carna Biosciences Inc.
  • Nov 12 2013   NTRC provides high-throughput screening services together with Pivot Park Screening Centre
  • Oct 14 2013   NTRC to partner with European centers of excellence in training network for next generation cancer researchers
  • Oct 13 2013   NTRC will present at BioEurope 2013
  • Sep 26 2013   Oncolines™ presented at the European Cancer Congress 2013
  • Nov 19 2012   NTRC and Carna join forces in the marketing of drug discovery services in Europe and Japan
  • Nov 13 2012   NTRC obtains exclusive license for Merck kinase candidate compounds
  • Jun 6 2012   NTRC starts at the Life Sciences Park Oss